Stoke Therapeutics Advances RNA Medicine with Strong Q2 Results

Stoke Therapeutics ( (STOK) ) has released its Q2 earnings. Here is a breakdown of the information Stoke Therapeutics presented to its investors.

Stoke Therapeutics is a biotechnology company focused on developing RNA-based medicines to restore protein expression, with a primary focus on treating severe genetic diseases such as Dravet syndrome and Autosomal Dominant Optic Atrophy (ADOA).

In its latest earnings report, Stoke Therapeutics highlighted significant progress in its clinical programs, including the dosing of the first patient in the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome and the initiation of a Phase 1 study for STK-002 in ADOA. The company also reported strong financial results with increased revenues and a solid cash position.

Key financial metrics for the second quarter of 2025 include a revenue increase to $13.8 million from $4.8 million in the same period last year, driven by collaborations with Acadia Pharmaceuticals and Biogen. Despite a net loss of $23.5 million, the company improved from the previous year’s loss, and it maintains a robust cash reserve of $355 million, expected to fund operations through mid-2028.

Stoke Therapeutics continues to advance its pipeline with promising data from long-term studies of zorevunersen, demonstrating durable reductions in seizures and cognitive improvements in Dravet syndrome patients. The company is also optimistic about the potential of STK-002 to address vision loss in ADOA patients, marking a significant step in expanding its therapeutic reach.

Looking ahead, Stoke Therapeutics remains focused on progressing its clinical trials and exploring new opportunities for its RNA-based therapies. The management is committed to delivering innovative treatments for severe genetic diseases, with upcoming data presentations and ongoing collaborations expected to drive future growth.